The New York Post (4/30, Steussy) reports “the American College of Radiology and the Society of Breast Imaging are now recommending that women as young as 30 get a risk assessment – such as a genetic test – to determine what kind of formal cancer screening they need.” According to the article, “The new guidelines were announced...as a way to encourage early detection among younger women with a higher risk for breast cancer.”
Aunt Minnie (4/27, Yee) reports screening mammography in women ages 40 to 49 “finds almost 20% more cancers than screening in women ages 50 and older, according to a presentation delivered at the American Roentgen Ray Society (ARRS) meeting in Washington, DC.” The article says the boost in cancer detection “increases the recall rate by only 1.5% and the biopsy rate by 0.1%,” according to researchers led by Dr. Abid Irshad from the Medical University of South Carolina.
Diagnostic Imaging (4/26) reports. “False-positive stereotactic vacuum-assisted breast biopsies (SVABs) do not appear to negatively impact screening mammography adherence, according to a study published in the Journal of the American College of Radiology.” Researchers “performed a retrospective review to evaluate whether false-positive SVABs affected subsequent mammographic screening adherence.”
Aunt Minnie (4/24, Forrest) reports that while “digital breast tomosynthesis (DBT) increases radiation exposure for women when used with digital mammography for screening, the combined dose remains well within safety standards, according to a study presented on Monday at the American Roentgen Ray Society (ARRS) meeting.” The article says the radiation dose delivered to women undergoing DBT in combination with 2D digital mammography “varies based on breast density as well as compressed breast thickness,” but in either case “the dose is well within established guidelines from the U.S. Food and Drug Administration.”
Aunt Minnie (4/23, Yee) reports overdiagnosis of breast cancer, “the detection of cancer on screening that would not necessarily become apparent in a woman’s lifetime,” is cited as “one of screening mammography’s biggest harms,” but its prevalence is not as high as previously thought, according to a study published in the May issue of Radiology.